References
- Prince H M, McCormack C, Ryan G, O'Keefe R, Seymour J, Baker C. Management of the primary cutaneous lymphomas. Aust J of Dermatology 2003; 44: 227–240
- Jaffey E, Harris N L, Stein H, Vardiman J W. World Health Organization Classification of Tumours – Pathology and Genetics; Tumours of haematopoietic and lymphoid tissues; Chapter 9: Immunodeficiency-associated lymphoproliferative disorders: Methotrexate-associated lymphoproliferative disorders. 270–271
- Friedberg J, Eisen H, Brennan D. Lymphoproliferative disorders following solid organ transplantation, Available at: www.utdol.com/application/topic.asp?file=tumourhiv/5265
- Thomason R W, Craig F E, Banks P M, Sears D L, Myerson G E, Gully M L. Epstein-Barr virus and lymphoproliferation in methotrexate-treated rheumatoid arthritis. Mod Pathol Mar, 1996; 9(3)261–266
- Paya C V, Fung J J, Nalesnik M A, Kieff E, Green M, Gores G, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517
- Fischer A, Blanche S, Le Bidois J, Bordigoni P, Garnier J L, Niaudet P, et al. Anti B cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1415
- Milpied N, Vasseur B, Parquet N, Garnier J L, Antoine C, Quartier P, et al. Humanised anti-CD20 monoclonal antibody (Rituximab) in post-transplant B lymphoproliferative disorder: A retrospective analysis in 32 patients. Ann Oncol 2000; 11: 113
- Oertel S H, Anagnostopoulos I, Bechstein W O, Liehr H, Riess H B. Treatment of post-transplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: A new drug therapy of patients with post-transplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2000; 69: 430
- Ganne V, Siddiqi N, Kamaplath B, Chang C C, Cohen E P, Bresnahn B A, et al. Humanised anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003; 17(5)417–422
- Wood A. Rituximab: An innovative therapy for Non-Hodgkin's lymphoma. Am J Health-Syst Pharm 2001; 58(3)215–232
- Entz-Werle N, Cojean N, Barats A, Dyer D, Munzer M, Uring-Lambert B, et al. Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab. Paediatric Transplantation 2003; 7(4)277–281